Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors

A method of identifying patients with ovarian cancer who are most likely to benefit from treatment with an IGF-1R kinase inhibitor, comprising:

• determining whether tumor cells from a sample of a patient's tumor possess a mutant K-RAS gene;
• and
• identifying the patient as one most likely to benefit from treatment with an IGF-1R kinase inhibitor if the tumor cells possess a mutant K-RAS gene.

A method for treating ovarian cancer in a patient, comprising administering to said patient a therapeutically effective amount of an IGF-1R kinase inhibitor if the patient has been diagnosed to be potentially responsive to an IGF-1R kinase inhibitor by determining that the tumor cells of the patient possess a mutant K-RAS gene.

A method for treating cancer in a patient, comprising administering to said patient a therapeutically effective amount of an IGF-1R kinase inhibitor if the patient has been diagnosed to be potentially responsive to an IGF-1R kinase inhibitor by determining that the tumor cells of the patient possess a mutant K-RAS or mutant B-RAF gene in the absence of a mutant PIK3CA gene.

A method of predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor in a patient, comprising:

• determining if tumor cells from a sample of a patient's tumor possess a mutant PTEN gene or a mutant PIK3CA gene;
• and concluding that if the tumor cells possess mutant PTEN or mutant PIK3CA, low sensitivity to growth inhibition by an IGF-1R kinase inhibitor is predicted in the patient, based upon a predetermined correlation of the presence of mutant PTEN or mutant PIK3CA with low sensitivity.

A method for treating cancer in a patient, comprising administering to said patient a therapeutically effective amount of an IGF-1R kinase inhibitor if the patient has been diagnosed to be potentially responsive to an IGF-1R kinase inhibitor by a determination that the tumor cells of the patient do not possess a mutant PTEN gene or a mutant PIK3CA gene.